(Q37776846)

23 August 2017

1 reference

title

Epithelial ovarian cancer: Focus on targeted therapy (English)

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

14 June 2024

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20674385

14 June 2024

author name string

Kyriaki Pliarchopoulou

1

1 reference

23 August 2017

Dimitrios Pectasides

2

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20674385

14 June 2024

publication date

2 August 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S104084281000171X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

https://api.elsevier.com/content/article/PII:S104084281000171X?httpAccept=text/plain

14 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Critical Reviews in Oncology Hematology

14 June 2024

published in

1 reference

23 August 2017

79

1 reference

23 August 2017

1

1 reference

23 August 2017

17-23

1 reference

New therapies for ovarian cancer: cytotoxics and molecularly targeted agents

23 August 2017

2

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

14 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Angiogenesis in normal and neoplastic ovaries

14 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition

14 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma

14 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer

14 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

A role for survivin in chemoresistance of endothelial cells mediated by VEGF

14 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

14 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

14 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

14 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

14 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer

14 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Epidermal growth factor receptor inhibitors in cancer treatment.

14 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer

14 June 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Studies with ZD1839 in preclinical models

14 June 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

14 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)

14 June 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

14 June 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.

14 June 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer

14 June 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study

14 June 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer

14 June 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies

14 June 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

14 June 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

14 June 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms

14 June 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

14 June 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.

14 June 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia

14 June 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

14 June 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Folate receptor alpha as a tumor target in epithelial ovarian cancer

14 June 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

14 June 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Hallmarks of 'BRCAness' in sporadic cancers

14 June 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth

14 June 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations

14 June 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?

14 June 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs

14 June 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells

14 June 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Protein kinase C isozymes as potential targets for anticancer therapy

14 June 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

Targeting Aurora kinases in ovarian cancer

14 June 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer

14 June 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.004

14 June 2024

Identifiers

1 reference

23 August 2017

1 reference